Simple blood test may flag heart danger in kidney patients
NCT ID NCT07141628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure levels of lipoprotein A, a type of fat in the blood, in 300 people with stage 4 chronic kidney disease. Researchers want to see if high levels are linked to future heart attacks, strokes, or worsening kidney function over 18 months. The goal is to find a better way to identify which patients are at highest risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could show that measuring lipoprotein A helps doctors better predict heart and kidney risks in people with chronic kidney disease.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks for links, not causes, and the 18-month follow-up may be too short to see clear patterns.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- One scan, many answers: can a new CT predict heart risks after stenting?
- Digital coaching aims to boost heart health in obesity
- Could a phone app be the key to managing kidney disease?